Physician profile
Jee Eun Lee Karl
NPI 1598070732
$1,021.13
in general payments reported to CMS, 2019-2025
21 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $44.18 · 2021: $94.96 · 2022: $75.77 · 2023: $138 · 2024: $154 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $240.85 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $105.39 | 2019-2024 | |
| Abbvie INC. | $93.15 | 2019-2025 | |
| Lilly USA, LLC | $78.79 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.24 | 2019-2020 | |
| Glaxosmithkline, LLC. | $73.19 | 2021-2025 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.73 | 2024-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $35.12 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $32.20 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $31.82 | 2021 | |
| Merck Sharp & Dohme LLC | $31.07 | 2025 | Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $28.20 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $25.95 | 2024 | |
| Amgen INC. | $18.48 | 2024 | Evenity, Prolia |
| Astellas Pharma US INC | $18.18 | 2023 | Veozah |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyera Pharmaceuticals, LLC | $17.98 | 2019 | |
| Avion Pharmaceuticals | $16.73 | 2023 | Balcoltra |
| Kaleo, INC. | $16.17 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $15.61 | 2019 | |
| Ironshore Pharmaceuticals INC. | $14.79 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jee Eun Lee Karl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.